Adage Capital Partners
LOGC

Adage Capital Partners’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Adage Capital Partners’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-800,000
Closed -$6.77M – 832
2020
Q2 		$6.77M Sell
800,000
-115,355
-13% -$759K 0.02% 577
2020
Q1 		$4.52M Sell
915,355
-331,199
-27% -$2.58M 0.01% 583
2019
Q4 		$8.97M Sell
1,246,554
-131,921
-10% -$1.19M 0.02% 554
2019
Q3 		$14.9M Buy
1,378,475
+78,475
+6% +$839K 0.04% 439
2019
Q2 		$16.9M Buy
1,300,000
+390,000
+43% +$5.18M 0.04% 401
2019
Q1 		$8.99M Hold
910,000
– – 0.02% 540
2018
Q4 		$9.46M Buy
+910,000
New +$11M 0.03% 517

Other funds holding LOGC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Adage Capital Partners's LOGC Position: Q3 2020 in Review

Adage Capital Partners sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2020, closing a stake of 800,000 shares — an estimated $6.77M sold.

Adage Capital Partners first reported a position in LOGC in Q4 2018 and held it in 7 quarters. The position peaked at $16.9M in Q2 2019. 51 funds tracked by Wall St. Rank hold LOGC as of Q3 2020.

  • Adage Capital Partners reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Adage Capital Partners sold 800,000 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $6.77M.
  • Adage Capital Partners first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 7 quarters.
  • Adage Capital Partners's LogicBio Therapeutics, Inc. Common Stock position peaked at $16.9M in Q2 2019.
  • 51 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Adage Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.